Tenofovir as a treatment option for multiple sclerosis

Area of Science:

• Neuroimmunology
• Virology
• Pharmacology

Background:

• Epstein-Barr virus (EBV) reactivation is implicated in multiple sclerosis (MS) pathogenesis.
• Antiretroviral medications used for Human Immunodeficiency Virus (HIV) infection can inhibit EBV.
• Tenofovir alafenamide (TAF) is a potent inhibitor of EBV lytic reactivation, while tenofovir disoproxil fumarate (TDF) has less potent activity.

Discussion:

• This case study explores the potential impact of differential EBV inhibition by antiretroviral drugs on MS activity.
• A patient with highly active MS and HIV experienced complete remission on TAF, a potent EBV inhibitor.
• Disease activity recurred upon switching to TDF, which has weaker EBV inhibitory effects, suggesting a link between EBV suppression and MS control.

Key Insights:

• Differential inhibition of Epstein-Barr virus (EBV) by antiretroviral drugs may influence multiple sclerosis (MS) disease activity.
• Tenofovir alafenamide (TAF) demonstrated efficacy in managing MS in an HIV-positive patient by suppressing EBV.
• The findings highlight the potential role of EBV-targeted antiretroviral therapy in MS management.

Outlook:

• Further clinical studies are warranted to investigate the efficacy of TAF and TDF in managing MS.
• Exploring the precise mechanisms by which these antiretroviral drugs affect MS pathogenesis is crucial.
• This research opens avenues for novel therapeutic strategies for MS leveraging antiviral properties of existing medications.